Skip to main content

Table 4 Sensitivity to clinically approved antineoplastic agents potentiated by cytochalasin B against multidrug resistant SKVLB1 human ovarian carcinoma

From: Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro

Time of exposure (Hours)

13.5

33

IC concentrations (μM)

IC90

FS

IC90

FS

Doxorubicin

 0 μM Cytochalasin B

5

-

5

-

 0.15 μM Cytochalasin B

2.5

2

2.5

2

 0.60 μM Cytochalasin B

1.3

4

1.3

4

Paclitaxel

 0 μM Cytochalasin B

>40

-

40

-

 0.15 μM Cytochalasin B

20

2

5

8

 0.60 μM Cytochalasin B

15

2.5

4

10

  1. FS fold sensitization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us